South San Francisco, CA — Sanam Pangali, serving as the Chief Legal Officer for ALUMIS INC. (NASDAQ:ALMS), finalized a series of stock transactions on July 6, 2026, as documented in a recent Securities and Exchange Commission filing. The executive disposed of 5,000 shares of ALUMIS INC. common equity, generating $140,000 in proceeds. At the time of the sale, the shares were valued at $28.00 each. Recent market data indicates the stock has since appreciated to $29.74, positioning it close to its 52-week peak of $30.60.
Market analysis tools suggest the current pricing may reflect an overvaluation relative to the company's intrinsic fair value. The timing of Pangali's sale is notable given this valuation context, as the executive's stock movement coincides with broader market interest in the firm's clinical pipeline.
The disposition of shares was preceded by the acquisition of 5,000 shares through the exercise of stock options. These options were originally priced at $5.06 per share, resulting in a total acquisition cost of $25,299. The option agreement features an expiration date of February 17, 2035. The vesting structure mandated that 25% of the shares vested on February 18, 2026, with the balance vesting in equal monthly installments over the subsequent 36 months. This vesting schedule is contingent upon continuous service to the issuer and includes provisions for acceleration under specific conditions.
Following these transactions, Pangali's direct holdings in ALUMIS INC. common stock stand at 11,111 shares. This executive activity unfolds against a backdrop of intensified analyst coverage and clinical data releases. Guggenheim recently upgraded its price target for Alumis to $34, maintaining a Buy rating. This adjustment followed the company's presentation of detailed results from its Phase III ONWARD1 and ONWARD2 studies. These trials evaluated the oral TYK2 inhibitor, envudeucitinib, for the treatment of psoriasis in a cohort of 840 patients. The data highlighted significant response rates and a favorable safety profile, with Alumis planning to submit a new drug application in the fourth quarter of 2026.
Stifel also reiterated a Buy rating and established a $44 price target, citing deepening PASI responses from the Phase 3 data presented at a dermatology conference. H.C. Wainwright maintained its Buy rating with a $25 target, emphasizing the potential competitive strength of the TYK2 inhibitor within the oral therapeutic category. Cantor Fitzgerald reaffirmed an Overweight rating, noting the company's approach toward a key Phase 2b readout for systemic lupus erythematosus.
The convergence of executive stock sales, analyst upgrades, and clinical trial milestones underscores the dynamic nature of Alumis's current operational phase. While the stock has climbed near its 52-week high, internal valuation metrics and executive transactions provide additional layers of context for investors monitoring the firm's trajectory.